BPC-157 is angiogenic and nitric-oxide-pathway driven for local tissue repair; Ipamorelin is a selective ghrelin-receptor agonist for systemic pulsatile GH release. Both have zero human RCTs for the use cases driving online interest, both are WADA-prohibited in different list categories, and neither is FDA approved.
Both peptides share a critical honest verdict: zero published human RCTs as of July 2026 for the indications most readers are evaluating. BPC-157 has zero human RCTs at all (animal-only evidence); Ipamorelin has pharmacodynamic data in healthy volunteers establishing GH pulsatility, but no completed human RCTs for body composition, anti-aging, or systemic recovery-sleep appeal. This page synthesizes the existing BPC-157 deep-dive and the Ipamorelin deep-dive; it does not introduce new evidence. If you are evaluating one peptide for a clinical decision, the underlying deep-dives are the authoritative references.
Each row states a claim that is supported by a specific peer-reviewed citation. PMIDs link to the corresponding PubMed record — open any of them to verify the underlying study directly. Tier badges follow the four-tier evidence language used across all PeptideDecoded content (human RCT → human observational → animal/preclinical → mechanistic/anecdote).
| Claim | BPC-157 evidence | Ipamorelin evidence |
|---|---|---|
| Sustainable preclinical body of evidence for primary indication | Strong (animal)Pharmacological profile across GI, tendon, vascular, and wound models. PMID: 34139902 | Moderate (animal / pharmacodynamic)Selective ghrelin-receptor agonism established in healthy-volunteer pharmacodynamic study. PMID: 9783708 |
| Tendon / ligament repair | Supportive (animal)Tendon, ligament, and bone healing consistently reported across rodent studies. PMID: 32628526 · PMID: 31800443 | Not establishedGH/IGF-1 → collagen synthesis is mechanistically plausible; no tendon-specific animal or human data for Ipamorelin. |
| GI / mucosal healing | Strong (animal)Original Sikiric GI-protection literature is the largest body of work for any peptide in this comparison. PMID: 32628526 | Exploratory (human, narrow indication)Novo Nordisk NNC 26-0161 Phase II programme explored post-operative ileus; results never published in a peer-reviewed venue. |
| Sleep architecture / slow-wave recovery | Not establishedNo published sleep-architecture or recovery-sleep studies for BPC-157. | Mechanism onlyGH pulsatility → slow-wave sleep is mechanistic, not RCT-established. PMID: 9783708 |
| Body composition / fat loss / muscle gain | NoneOff-target for the peptide — no animal or human studies. | NoneGH elevation is a surrogate, not an outcome. Zero published human RCTs using body-composition endpoints. |
| Anti-aging / longevity outcomes | NoneNo published preclinical or clinical anti-aging outcomes for BPC-157. | NoneGH-axis pharmacology is a surrogate, not an outcome. Zero published human RCTs for any longevity endpoint. |
| Human randomized controlled trial (any indication) | NoneZero published human RCTs as of July 2026. | NoneZero published peer-reviewed human RCTs for body composition, anti-aging, or recovery indications. |
| WADA status | Prohibited (S0 — at all times, no TUE pathway) | Prohibited (S2 — peptide hormones / GH secretagogues, at all times) |
| FDA status | Not approved. Excluded from 503A compounding under FDA Category 2 bulk substance. | Not approved. No compounding monograph; subject to the July 2026 FDA reclassification review. |
Citations reused from the BPC-157 deep-dive and the Ipamorelin deep-dive. PMIDs are limited to the set already cited in the underlying deep-dives (— PubMed identifiers 34139902, 32628526, 31800443, 9783708) — no new citations introduced.
Three side-by-side cards for direct comparison. The "Route / dosing" rows reflect community-reported ranges from peptide forums and compounding pharmacies — they are not clinically validated dosing protocols, and no human trial supports them.
Three honest verdicts. Each mirrors the same evidence-gap framing used in the underlying deep-dives — choosing one peptide over another does not establish human efficacy for either, it only frames where the animal evidence is strongest.
BPC-157 is the more evidence-supported option when the use case targets a specific local tissue. The Sikiric lab's tendon and MSK data is the most extensive of any peptide commonly discussed in recovery communities (PMID: 32628526; PMID: 31800443). The mechanistic story — VEGF-driven angiogenesis + EGR-1 collagen signaling — is biologically plausible and consistent across multiple animal models. Caveats: zero human RCTs as of 2026, and the evidence base is dominated by a single research group at the University of Zagreb with disclosed patent interests. Animal-to-human translation is not assumed.
Ipamorelin's distinguishing feature is its selective ghrelin-receptor agonism, established in the original Raun healthy-volunteer pharmacodynamic study (PMID: 9783708): clean GH pulses without meaningful cortisol or prolactin co-activation. That profile is what justifies its adoption in recovery-sleep protocols. Caveats: GH elevation is a surrogate, not an outcome — zero published human RCTs using body-composition, anti-aging, or recovery endpoints. GH pulse ≠ validated efficacy for any of these indications.
Combining BPC-157 and Ipamorelin is a common recovery-stack protocol because the mechanisms are complementary, not redundant: BPC-157 builds local blood supply (VEGF / NO) while Ipamorelin raises systemic GH pulses (PMID: 9783708). They hit different steps in the healing and recovery cascade. Caveats: the rationale is mechanistic complementarity with zero published human safety or efficacy data on the pair; both peptides' regulatory exposure stacks (BPC-157 under WADA S0, Ipamorelin under S2); BPC-157 excluded from 503A compounding under FDA Category 2, Ipamorelin in regulatory gray zone subject to the July 2026 FDA reclassification.
"Evidence tier" is the most important field in every claim above. Two peptides can share a use case while having radically different evidence behind that use case. The badge colors map to the same four-tier language used across all PeptideDecoded deep-dives:
For deeper context on how to evaluate any peptide claim — peer review, COI checks, red flags, and a 5-question pre-purchase checklist — see How to Verify Peptide Claims and the Editorial Standards page.
This comparison is the synthesis. The full evidence reviews are the underlying references — open either one if you want to evaluate a specific claim, verify a citation, or read the COI disclosure in detail.
Competitive athletes (WADA S0 + S2): BPC-157 is prohibited at all times under S0 (non-approved substances); Ipamorelin is prohibited at all times under S2 (peptide hormones / GH secretagogues). A positive test for either results in a ban, and there is no Therapeutic Use Exemption (TUE) pathway for either compound.
Anyone seeking an FDA-approved therapy: neither peptide is approved for any human indication. BPC-157 is excluded from 503A compounding under FDA Category 2. Ipamorelin has no compounding monograph and sits in regulatory gray zone subject to the July 2026 FDA reclassification review of peptide hormones. Stacking amplifies regulatory exposure without adding evidence.
Anyone needing proven human efficacy: zero published human RCTs for both peptides as of July 2026. Community-reported outcomes are not clinical evidence. If you need a therapy with validated human efficacy, neither peptide is the right starting point — much less the combination.
This comparison page is a research summary, not medical advice. PeptideDecoded does not sell peptides, recommend vendors, provide dosing protocols, or make claims about safety or efficacy for any specific individual.
Work with a qualified physician who can evaluate your full medical history, current medications, and individual risk factors before making any decision about peptides — whether FDA-approved, compounded, or sold as research chemicals.